Aicardi-Goutières syndrome (AGS) is a genetic encephalopathy whose clinical features mimic those of acquired in utero viral infection. AGS exhibits locus heterogeneity, with mutations identified in genes encoding the 3 r5 exonuclease TREX1 and the three subunits of the RNASEH2 endonuclease complex. To define the molecular spectrum of AGS, we performed mutation screening in patients, from 127 pedigrees, with a clinical diagnosis of the disease. Biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and RNASEH2C were observed in 31, 3, 47, and 18 families, respectively. In five families, we identified an RNASEH2A or RNASEH2B mutation on one allele only. In one child, the disease occurred because of a de novo heterozygous TREX1 mutation. In 22 families, no mutations were found. Null mutations were common in TREX1, although a specific missense mutation was observed frequently in patients from northern Europe. Almost all mutations in RNASEH2A, RNASEH2B, and RNASEH2C were missense. We identified an RNASEH2C founder mutation in 13 Pakistani families. We also collected clinical data from 123 mutation-positive patients. Two clinical presentations could be delineated: an early-onset neonatal form, highly reminiscent of congenital infection seen particularly with TREX1 mutations, and a later-onset presentation, sometimes occurring after several months of normal development and occasionally associated with remarkably preserved neurological function, most frequently due to RNASEH2B mutations. Mortality was correlated with genotype; 34.3% of patients with TREX1, RNASEH2A, and RNASEH2C mutations versus 8.0% RNASEH2B mutation-positive patients were known to have died ( ). Our analysis defines the phenotypic P p .001 spectrum of AGS and suggests a coherent mutation-screening strategy in this heterogeneous disorder. Additionally, our data indicate that at least one further AGS-causing gene remains to be identified.
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In 1984, Jean Aicardi and Françoise Goutières, two eminent French pediatric neurologists, reported eight children from five families with an early-onset encephalopathy characterized by basal-ganglia calcification, whitematter abnormalities, and a chronic cerebrospinal fluid (CSF) lymphocytosis (MIM 225750). 1 The presence of sib-ling recurrences, affected females, and parental consanguinity suggested that the condition was inherited as an autosomal recessive trait. However, the authors highlighted the risk of misdiagnosis of this disorder as the sequelae of congenital infection, an observation that subsequently led to the finding of raised levels of the antiviral 714 The American Journal of Human Genetics Volume 81 October 2007 www.ajhg.org Figure 1 . Numbers and percentages of AGS-affected families with biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and RNA-SEH2C; single RNASEH2A, RNASEH2B, and TREX1 mutations; and those with no identifiable mutation(s). cytokine interferon alpha (IFN-a) in the CSF of affected children. 2 Phenotypic variability was recognized in the original description of AGS and has since been confirmed by others. 3, 4 Patients with apparently static or slowly progressive disease, sometimes presenting after several months of normal development, have been reported, 1,5 whereas other children have been reported with a neonatal onset of features and early death. 6 Notably, a number of earlypresenting cases have exhibited hepatosplenomegaly, thrombocytopenia, and congenital microcephaly, further emphasizing the clinical overlap with acquired in utero infection. 3 AGS is a genetically heterogeneous disorder. Elsewhere, we localized the position of a gene (AGS1) causing AGS on chromosome 3p21 7 and demonstrated that Cree encephalitis, a severe infantile neurodegenerative disorder found among the Canadian Cree Indian tribe of northern Quebec, is allelic to AGS. 8 Subsequently, we defined, again by linkage analysis in consanguineous families, a second disease locus (AGS2) on chromosome 13q14-21. 9 Recently, we described mutations in genes encoding the 3 r5 exonuclease TREX1 (or, DNase III [MIM 606609; Gen-Bank transcript AAK07616 and nucleotide sequence NM_ 033627], which causes AGS1) 10 11 in patients with AGS. The genetic heterogeneity of the disease thus extends to include at least four loci, with strong evidence of a common underlying pathogenic mechanism.
Here, we present clinical and molecular data from a large cohort of AGS cases that define the phenotypic spectrum of AGS and suggest a coherent mutation-screening strategy for this heterogeneous disorder. Our data also indicate that at least one further AGS-causing gene, accounting for the disease in 17% of AGS-affected families in our study, remains to be identified.
Material and Methods

Subjects
Subjects with a clinical diagnosis of AGS from 127 independent pedigrees were recruited internationally through collaborating physicians and the International Aicardi-Goutières Syndrome Association. Twenty-five families were seen by one of us (Y.J.C.). For the remainder, information was provided by the clinician responsible for the care of the patient. Clinical, neuroimaging, and laboratory data were obtained from medical records, magnetic resonance imaging (MRI), and CT scans. Information about every clinical characteristic was not available for all patients. All mutation-negative families and those families in which only one mutation could be identified included at least one child fulfilling the following diagnostic criteria: neurological features of an encephalopathy, intracranial calcification, negative investigations for common prenatal infections, a CSF white-cell count (WCC) у5 white cells/mm 3 , and/or raised levels of IFN-a (12 IU/liter or 110 pg/ml) in the CSF. With consent, blood samples were obtained from affected children, their parents, and unaffected siblings. The study was approved by a U.K. Multicentre Research Ethics Committee (reference number 04:MRE00/19).
Mutation Analysis
Genomic DNA was extracted from peripheral-blood leukocytes by standard methods. PCR amplification of all coding exons and conserved splice sites of TREX1 (AGS1), RNASEH2A (AGS4), RNA-SEH2B (AGS2), and RNASEH2C (AGS3) was performed (primer sequences available on request). Purified PCR-amplification products were sequenced using dye-terminator chemistry and were electrophoresed on ABI 3700 (Applied Biosystems), ABI 3100, or MegaBace500 (Amersham Pharmacia) capillary sequencers. Additionally, high-resolution melting curve analysis (MCA) was employed to screen RNASEH2A and RNASEH2B, with use of a Light-Scanner (Idaho Technology) operating LightScanner v1.0.364 software. PCR incorporated the fluorescent dye LCGreenϩ, and, after completion, microtiter plates were transferred to the Light-Scanner, with fluorescence data collection over the temperature range 70ЊC-95ЊC, as samples were melted. Samples were run both "neat" and "spiked" with wild-type PCR product, to ensure detection of homozygous variants. Data were analyzed using the "manual scanning" setting. For DNA fragments with more than one melting domain, as well as examination of the entire melting curve, each separate melting domain was analyzed individually. Samples in which the melting curve deviated from the wild-type control were subjected to DNA sequencing. Mutations were classified as "null" if they were predicted to result in premature protein termination (including frameshifts, nonsense mutations, and mutations altering splice-donor and -acceptor sequences); missense mutations were defined as "those causing the substitution of one amino acid for another." One hundred European control alleles were sequenced for all four genes, and, in the case of RNA-SEH2C, 100 South Asian alleles were also analyzed.
Statistical Analysis
x 2 analyses, Kruskal-Wallis tests, and Mann-Whitney U tests for nonparametric variables were performed using the Statistical Package for the Social Sciences for Windows, version 12.01 (SPSS).
Results
Genetic Findings
Biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and RNASEH2C were observed in 31, 3, 47, and 18 families, respectively. In three families, we could identify only a single RNASEH2B mutation. In one family, we identified a single mutation in RNASEH2A, and, in one further patient, we saw two putative RNASEH2A mutations on the identified. An asterisk (*) denotes polymorphisms included in the SNP database; a double asterisk (**) denotes synonymous changes not found in controls or annotated as a SNP; ¶ denotes polymorphisms found in controls; † denotes polymorphisms found in combination with RNASEH2B mutations; ‡ denotes putative mutation found in patients with only a single identified RNASEH2A change; a number sign (#) denotes mutations found on one allele in a single patient.
same allele. In one patient, a single de novo heterozygous TREX1 mutation was observed. Additionally, in 22 families, no mutations were found ( fig. 1 and table 1 ). None of the identified mutations was annotated as a SNP in the available databases, and none was present in alleles from control subjects. Where tested, mutations segregated with the disease in all families, and, except in the case of the de novo heterozygous TREX1 mutation, all available parents were heterozygous for a single mutation. TREX1 is a single-exon gene encoding a 314-aa protein. Mutations were seen throughout the gene ( fig. 2 ). Eleven mutations were null alleles. Eighteen families, 14 of which were of northern European origin, were homozygous (15) or compound heterozygous (3) for a c.341GrA transition (R114H). Notably, all R114H homozygotes were also homozygous for the T allele of a SNP at c.531. This allele exhibits highly significant (x 2 test ) over-represen-P ! .001 tation in patients compared with controls (with a T allele population frequency of 0.4), suggesting that the R114H change might be an ancient founder mutation.
A total of 20 distinct mutations were identified in RNASEH2B (a 308-aa protein) ( fig. 3 ). All were missense changes, except for five splice acceptor/donor mutations and two stop mutations; the 12 affected individuals carrying these were all compound heterozygotes; the second mutation was a missense change. All 50 families with a change identified in RNASEH2B harbored at least one mutation in exon 2, 6, or 7. The recurrent c.529GrA (A177T) mutation was seen in a panethnic cohort of patients, indicating that this is a mutation hotspot. In three families, we could identify only a single RNASEH2B mutation. In one of these families, the mutation had been maternally inherited, whereas, in the other two families, parental samples were unavailable. The two heterozygous mutations observed in these three pedigrees, c.529GrA and c.488CrT, were seen recurrently in other cases.
We identified six distinct RNASEH2C (164-aa) missense mutations in 18 families ( fig. 4 ). Thirteen of these families were of Pakistani origin, all of whom were homozygous for the R69W (c.205CrT) mutation on a common haplotype (data not shown), suggesting an ancient founder effect. The remaining mutations were seen in a panethnic cohort of patients.
Four children from three families were found to have biallelic mutations in RNASEH2A (299 aa) ( fig. 5 ). Four of five mutations, one of which occurred in homozygous form, were missense. In one family, we identified a single mutation, c.704GrA (R236Q), in RNASEH2A that had been inherited. In another patient, we identified two putative RNASEH2A mutations, c.717dup GC and c.719CrT 7 . Age at death (in years) of patients with TREX1, RNASEH2A, RNASEH2B, and RNASEH2C mutations; x 2 test comparing number of deaths among children with TREX1, RNASEH2C, and RNASEH2A mutations against number of deaths among children with RNASEH2B mutations ( ). P p .001 (T241M), on the same allele. Parental samples were unavailable in this case. Finally, a number of polymorphisms were also identified in the RNASEH2A gene.
Clinical Findings
Clinical data were collected for 123 individuals from 94 families with mutations in TREX1, RNASEH2A, RNASEH2B, or RNASEH2C. The majority of children were born at term, with a normal birth weight and head circumference, and were discharged to home soon after delivery. However, 23 children (19 with TREX1 mutations, 3 with RNASEH2C mutations, and 1 with a homozygous RNASEH2A mutation) were affected at birth and required immediate support (table 2) . These children presented with abnormal neurology, acted jittery, and fed poorly. Eight experienced neonatal seizures, and 15 demonstrated liver involvement, with hepatosplenomegaly and/or raised transaminase levels. Fifteen children had a thrombocytopenia, of whom five required one or more platelet transfusions.
All other children presented at variable periods beyond the first few days of life with, in the majority of cases, the stereotypical subacute onset of a severe encephalopathy characterized by irritability, inconsolable crying, intermittent sterile pyrexias (40%), and a loss of skills. These episodes usually lasted several months, beyond which time the condition stabilized. Thereafter, no further disease progression was generally observed. Children with RNASEH2B mutations presented significantly later than www.ajhg.org did those with mutations in TREX1, RNASEH2C, or RNA-SEH2A (Mann-Whitney U test, ) ( fig. 6 ); five chil-P ! .0005 dren had onset of symptoms at or beyond age 12 mo, after a completely normal period of development.
The neurological phenotype of all patients was remarkably consistent, although variations were observed in the severity of the associated neurological handicap. Typically, patients were left with peripheral spasticity; dystonic posturing, particularly of the upper limbs; truncal hypotonia; and poor head control. Seizures were reported in 53% of patients. A number of children were noted to demonstrate a marked startle reaction to sudden noise, and, in several cases, the differentiation from epilepsy was uncertain. Almost all patients were severely intellectually and physically impaired. However, six children with RNASEH2B mutations had relatively preserved intellectual function, with good comprehension and at least some retained speech. One of these patients is of normal intelligence at age 19 years. A discrepancy in the severity of the neurological outcome was observed between siblings in several families. Most patients exhibited a severe acquired microcephaly, but, in those children with preserved intellect, the head circumference was normal. Hearing was reported as normal in almost every case. Visual function varied from normal to cortical blindness. Ocular structures were almost invariably normal on examination.
Of all children with TREX1, RNASEH2A, and RNASEH2C mutations, 34.3% were known to have died, the majority (81%) by age 10 years ( fig. 7) . In contrast, only 4 (8%) of 50 patients with RNASEH2B mutations were deceased (x 2 test, ), and 7 individuals with mutations in this P p .001 gene are known to be aged 118 years (the oldest known patient is aged 25 years).
Chilblain lesions were reported in 43% of patients and were associated with mutations in all four genes. The lesions were usually situated on the feet but sometimes also affected the hands and outer rim of the ears ( fig. 8 ). Many parents reported a direct relationship with cold temperatures, so the lesions were considerably worse during winter months.
A number of rarer features were observed (table 3) , including raised levels of autoantibodies in six children, treated hypothyroidism in an additional two cases, and insulin-dependent diabetes mellitus (IDDM) in two other patients.
Radiographic Findings
Neuroimaging demonstrated intracranial calcification variably involving the basal ganglia, dentate nuclei of the cerebellum, and deep white matter ( fig. 9 ). Additionally, there were associated abnormalities of the white matter, with, in milder cases, high signal on T2-weighted MRI situated at the anterior and posterior poles of the lateral ventricles and, in more severely affected patients, a striking frontotemporal leukodystrophy with temporal cystic lesions ( fig. 10 ). In those subjects presenting in the perinatal period, calcifications and white-matter disease were evident as early as the 1st d of life. Cortical atrophy was a common feature in later scans, and a number of children demonstrated significant brain-stem and cerebellar atrophy. Thinning and, in one subject, complete absence of the corpus callosum were also observed. 
Laboratory Findings
Where assayed, the number of white cells in the CSF was normal (!5 cells/mm 3 ) on 32 of 137 occasions (table 4) . The CSF WCC tended to fall with age, and the oldest age at which a level 15 cells/mm 3 was documented was 9 years (Kruskal-Wallis test comparing CSF WCC with age group, ) ( fig. 11 ). CSF IFN-a was recorded as elevated on P ! .0005 74 of 81 occasions tested. Again, levels of IFN-a tended to fall with age (Kruskal-Wallis test comparing CSF IFN-a with age group, ) ( fig. 12 ). Of note, on 15 of 73 P ! .0005 occasions where both were measured, the CSF WCC was normal when the IFN-a level was raised. Conversely, three children demonstrated a normal IFN-a titer with a raised number of CSF white cells (table 5) .
Pterin levels were recorded in 15 children (table 6) . Elevated levels of neopterin correlated well with raised num-bers of CSF white cells and CSF IFN-a titers, although, on two occasions, pterin analysis was normal in the presence of a CSF lymphocytosis, whereas, in two cases, there was marked elevation of CSF pterins with no associated increase in CSF white-cell numbers.
Discussion
AGS is one of a number of disorders whose clinical features mimic the sequelae of in utero viral infection. 1, [12] [13] [14] [15] [16] These conditions are important to recognize because of the associated high risk of recurrence. Our experience indicates that the possibility of a genetic disorder in subjects with AGS is sometimes unrecognized until the birth of a second affected child. In this regard, we note that no mention was made of such genetic disorders in a recent review of congenital infection. 17 We suggest that an absence of definitive evidence of an infectious agent in these circumstances should always raise the suspicion of AGS.
A subgroup of AGS-affected patients, typically those with TREX1 mutations, presented at birth with abnormal neurology, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly reminiscent of congenital infection. All other children presented at variable times beyond the first few days of life, frequently after a period of apparently normal development. The majority of these later-presenting cases exhibited a severe encephalopathy with subacute onset that was characterized by extreme irritability, intermittent sterile pyrexias, a loss of skills, and a slowing of head growth. This encephalopathic phase usually lasted several months. Interestingly, the opinion of most pediatricians involved in the care of these children was that there was no disease progression beyond the encephalopathic period. When death occurred, the death was usually considered not to be due to a regressive process but to be secondary to the neurological damage incurred during the initial disease episode. RNA-SEH2B mutations were associated with a significantly later age at presentation, at or after age 12 mo in five cases, and a lower mortality, with seven patients known to be alive beyond age 18 years with no signs of disease progression. Also of note, six affected individuals with RNA-SEH2B mutations demonstrated relatively preserved inwww.ajhg.org
The American Journal of Human Genetics Volume 81 October 2007 721 Figure 11 . CSF white-cell counts by age in patients with TREX1, RNASEH2A, RNASEH2B, and RNASEH2C mutations. With Kruskal-Wallis test comparing CSF WCC/mm 3 with age group, . P ! .0005 Figure 12 . CSF IFN-a titers by age in patients with TREX1, RNASEH2A, RNASEH2B, and RNASEH2C mutations. With Kruskal-Wallis test comparing CSF IFN-a IU/liter with age group, . P ! .0005 tellectual function; one patient has a completely normal intelligence quotient and head circumference at age 19 years, and his only feature is a spastic cerebral palsy with associated intracranial calcification.
The observation of changes on brain imaging at birth indicates an in utero onset of the disease process, in keeping with the recording of prenatal raised levels of IFN-a. 18 In contrast, our data also highlight the onset of AGS after many months of normal development, raising the possibility that the condition might occur in considerably older individuals too. The stimulus for the disease onset is unknown, and why the disease tends to "burn out" after several months is also not understood.
The cardinal features of AGS on brain imaging were intracranial calcification, a leukodystrophy, and cerebral atrophy. The distribution and extent of the calcification was variable and, in some cases, was observed in a periventricular distribution highly suggestive of congenital infection. Affected sibling pairs have been described as discordant for the presence of intracranial calcification, so this feature should not be considered a prerequisite for the diagnosis of AGS. 1 Additionally, in several of our patients, the intracranial calcification became evident only over a period of months. Of importance, intracranial calcification is not always recognized on MRI, the initial imaging modality employed in most medical facilities. Consequently, AGS should be considered in the differential diagnosis of an unexplained leukoencephalopathy, and CT scanning is warranted in cases conforming to the clinical scenarios we have outlined above. Of further note, some patients demonstrated marked frontotemporal white-matter involvement with cyst formation, so that Alexander disease (MIM 203450) and vanishing white-matter disease (MIM 603896) were considered and tested for.
We identified 99 families with biallelic mutations in one of the four genes known to cause AGS. Of these families, 78.8% had mutations in either TREX1 or RNASEH2B. Moreover, all the patients with RNASEH2B mutations harbored at least one mutation in exon 2, 6, or 7. Thus, an initial screen of TREX1 plus these three RNASEH2B exons, together with an analysis for the recurrent c.205CrT (R69W) RNASEH2C mutation in Pakistani patients, is likely to identify 90% of all AGS-affected patients with mutations in one of these four genes. In four families, we were able to identify only a single RNASEH2A (one family) or RNASEH2B (three families) mutation, and one further child carried two putative RNASEH2A mutations on the same allele; these cases are under further study. In addition, we studied 22 families in whom no AGS1-4 mutations could be identified. Given the high detection rate of biallelic mutations in AGS1-4, this finding strongly suggests further genetic heterogeneity. Finally, only a single patient was observed with a de novo heterozygous TREX1 mutation, indicating that such cases are unusual. 19 The majority of TREX1 mutations are null alleles that are predicted to produce truncated protein, which might be inactive or disrupt protein complexes in the cell. Our recent description of heterozygous TREX1 mutations as a cause of dominant AGS suggests that some mutations may have a dominant negative effect. 19 Additionally, multiple patients are homozygous or compound heterozygous for a recurrent amino acid substitution, R114H, known to be involved in stabilization of the TREX1 dimer 20 and that appears to abrogate TREX1 activity. 10 In contrast to TREX1, almost all mutations identified in RNASEH2A, RNASEH2B, and RNASEH2C are missense changes, which suggests a hypomorphic effect rather than a complete loss of RNA-SEH2 enzyme function. Indeed, this mutational spectrum raises the possibility that biallelic null alleles in any of these three genes might be lethal during embryonic development.
Minimum diagnostic criteria for AGS are difficult to define. We have already highlighted above the absence of intracranial calcification in some cases of AGS. A CSF lymphocytosis was originally described as a primary diagnostic feature of the disease and was posited to differentiate AGS from pseudo-TORCH syndrome. 14 However, it is well recognized that the level of white cells and IFN-a in the CSF of AGS-affected patients falls to normal over the first few years of life. 21 Moreover, in our series, a normal CSF WCC was documented in the presence of elevated CSF IFN-a titers on 15 occasions. Blau et al. 22 recently described a possible variant of AGS associated with high levels of CSF pterins. A number of mutation-positive AGS subjects in our series demonstrated a similar pterin profile, which should now be considered a marker of AGS. Whether the cases described by Blau et al. 22 have AGS or a separate condition remains to be determined.
The chilblain lesions 23 seen in 43% of AGS cases provide a useful clinical marker of the disease and indicate an immune pathology. The observation of a small number of AGS-affected children with autoantibodies, hypothyroidism, and IDDM also suggests immune dysfunction. We recently described heterozygous TREX1 mutations in an autosomal dominant cutaneous form of systemic lupus erythematosus (SLE [MIM 152700]) called "familial chilblain lupus" (MIM 610448). 19 The precise functions of TREX1 and the RNASEH2 complex are unknown. We predict that these nucleases are involved in removing nucleic acid species produced during apoptosis and that a failure of this process results in activation of the innate immune system. 24, 25 This hypothesis would explain the phenotypic overlap of AGS with congenital infection and some aspects of SLE, [26] [27] [28] [29] where an IFN-a-mediated innate immune response is triggered by viral and host nucleic acids, respectively. 30, 31 
